Jian Zhang1, Fei Yang2, Yong Ding3, Linlin Zhen4, Xuedong Han4, Feng Jiao5, Jinhai Tang6. 1. Department of General Surgery, Nanjing Medical University Affiliated Jiangsu Cancer Hospital Nanjing 210009, China ; Department of General Surgery, Huai'an First People's Hospital, Nanjing Medical University Huai'an, Jiangsu 223300, China. 2. Department of Oncology, Huai'an Second People's Hospital Huai'an, Jiangsu 223002, China. 3. Department of General Surgery, The People's Hospital of Hong'ze County Hong'ze, Jiangsu 223100, China. 4. Department of General Surgery, Huai'an First People's Hospital, Nanjing Medical University Huai'an, Jiangsu 223300, China. 5. Department of General Surgery, 82 Hospital of PLA Huai'an, Jiangsu 223001, China. 6. Department of General Surgery, Nanjing Medical University Affiliated Jiangsu Cancer Hospital Nanjing 210009, China.
Abstract
BACKGROUND AND PURPOSE: L1 cell adhesion molecule (L1CAM) has been observed to be aberrantly expressed and implicated in progression of several types of human cancers. However, its roles in breast cancer have not been fully elucidated. In this study, we aimed to investigate the clinical significance of L1CAM in human breast cancer and to validate whether it participates in cancer cell migration and invasion. METHODS: Immunohistochemical analysis of 100 breast cancer and matched non-cancerous breast tissues was performed to detect the expression and sub-cellular localization of L1CAM protein. Its associations with clinicopathological characteristics of breast cancer patients were statistically analyzed and its phenotypic effects were also evaluated in vitro. RESULTS: Of the 100 breast cancer patients, 89 (89.0%) were positive for L1CAM immunostaining localized in the membrane of cancer cells. The immunoreactive scores of L1CAM protein in breast cancer tissues were significantly higher than those in matched non-cancerous breast tissues (P<0.05). Chi-Square analysis showed the significant associations between L1CAM overexpression and high tumor stage (P=0.01), advanced tumor grade (P=0.03), positive lymph node metastasis (P=0.01) and tumor recurrence (P=0.01) in breast cancer patients. Moreover, we found that RNA interference-mediated knockdown of L1CAM could inhibit the migration and invasion abilities of breast cancer cells in vitro. CONCLUSIONS: Our results suggest that the overexpression of L1CAM may be related to several established markers of poor prognosis in breast cancer patients. L1CAM might be a potential therapeutic target against metastatic breast cancer.
BACKGROUND AND PURPOSE:L1 cell adhesion molecule (L1CAM) has been observed to be aberrantly expressed and implicated in progression of several types of humancancers. However, its roles in breast cancer have not been fully elucidated. In this study, we aimed to investigate the clinical significance of L1CAM in humanbreast cancer and to validate whether it participates in cancer cell migration and invasion. METHODS: Immunohistochemical analysis of 100 breast cancer and matched non-cancerous breast tissues was performed to detect the expression and sub-cellular localization of L1CAM protein. Its associations with clinicopathological characteristics of breast cancerpatients were statistically analyzed and its phenotypic effects were also evaluated in vitro. RESULTS: Of the 100 breast cancerpatients, 89 (89.0%) were positive for L1CAM immunostaining localized in the membrane of cancer cells. The immunoreactive scores of L1CAM protein in breast cancer tissues were significantly higher than those in matched non-cancerous breast tissues (P<0.05). Chi-Square analysis showed the significant associations between L1CAM overexpression and high tumor stage (P=0.01), advanced tumor grade (P=0.03), positive lymph node metastasis (P=0.01) and tumor recurrence (P=0.01) in breast cancerpatients. Moreover, we found that RNA interference-mediated knockdown of L1CAM could inhibit the migration and invasion abilities of breast cancer cells in vitro. CONCLUSIONS: Our results suggest that the overexpression of L1CAM may be related to several established markers of poor prognosis in breast cancerpatients. L1CAM might be a potential therapeutic target against metastatic breast cancer.
Authors: Kai Doberstein; Patrick N Harter; Uwe Haberkorn; Niko P Bretz; Bernd Arnold; Rafael Carretero; Gerhard Moldenhauer; Michel Mittelbronn; Peter Altevogt Journal: Int J Cancer Date: 2014-09-25 Impact factor: 7.396
Authors: H Zhang; C C L Wong; H Wei; D M Gilkes; P Korangath; P Chaturvedi; L Schito; J Chen; B Krishnamachary; P T Winnard; V Raman; L Zhen; W A Mitzner; S Sukumar; G L Semenza Journal: Oncogene Date: 2011-08-22 Impact factor: 9.867
Authors: Kaja Lund; Jennifer L Dembinski; Nina Solberg; Alfonso Urbanucci; Ian G Mills; Stefan Krauss Journal: PLoS One Date: 2015-04-10 Impact factor: 3.240
Authors: Esperanza Martín-Sánchez; Saioa Mendaza; Ane Ulazia-Garmendia; Iñaki Monreal-Santesteban; Idoia Blanco-Luquin; Alicia Córdoba; Francisco Vicente-García; Noemí Pérez-Janices; David Escors; Diego Megías; Paula López-Serra; Manel Esteller; José Juan Illarramendi; David Guerrero-Setas Journal: Oncotarget Date: 2017-02-28
Authors: Fanny M Deschepper; Roberta Zoppi; Martina Pirro; Paul J Hensbergen; Fabio Dall'Olio; Maximillianos Kotsias; Richard A Gardner; Daniel I R Spencer; Paula A Videira Journal: Int J Mol Sci Date: 2020-11-05 Impact factor: 5.923